Recently, disease-modifying therapies have revolutionized the therapeutic paradigm for patients diagnosed with early Alzheimer's disease. Monoclonal antibodies targeting amyloid protofibrils offer meaningful clinical slowing for appropriately selected individuals. However, practicing physicians encounter significant clinical safety challenges, particularly amyloid-related imaging abnormalities, commonly recognized as ARIA. Consequently, identifying reliable prognostic markers of lecanemab ARIA risk remains an urgent priority for modern clinical neurology. Emerging real-world evidence now links lower baseline cerebrospinal fluid amyloid-beta 42 concentrations directly to an elevated risk of these neuroimaging adverse events. Therefore, evaluating baseline biochemical profiles enables clinicians to stratify patient risk effectively before initiating intravenous therapy.

Real-World Cohort Evidence and Trial Findings

In a newly published cohort evaluation, clinical researchers investigated ninety-seven patients receiving lecanemab for early symptomatic Alzheimer's disease in routine clinical practice. Among this representative cohort, eleven individuals developed documented neuroimaging abnormalities during active therapy. Notably, baseline laboratory analyses revealed that cerebrospinal fluid amyloid-beta 42 levels were substantially lower in patients who subsequently developed neuroimaging complications than in unaffected peers. Specifically, the mean baseline concentration reached 483.2 picograms per milliliter in affected patients, compared to 667.4 picograms per milliliter in individuals who remained completely event-free.

Furthermore, statistical analyses confirmed that this quantitative disparity achieved clear significance, highlighting its clinical utility. While initial registration trials highlighted genetic status as the main safety determinant, this real-world investigation underscores biochemical fluid dynamics. Therefore, clinicians can observe how baseline biofluid metrics provide objective risk stratification before administering antibody infusions. In addition, real-world cohorts encompass broader patient demographics than selective clinical trials, making these observations exceptionally relevant to daily medical practice. Consequently, measuring pretreatment fluid biomarkers helps healthcare teams anticipate neurovascular vulnerability and tailor patient surveillance.

Evaluating Pathophysiology and Lecanemab ARIA Risk

Understanding why baseline biofluid markers correlate with neuroimaging abnormalities requires evaluating cerebral vascular pathology. In patients with Alzheimer's disease, amyloid-beta 42 clearance from interstitial brain fluid into cerebrospinal pathways progressively diminishes as vascular deposits accumulate. Consequently, marked depletion of cerebrospinal fluid amyloid reflects extensive parenchymal plaque accumulation and pronounced cerebral amyloid angiopathy. When therapeutic monoclonal antibodies bind these vascular amyloid aggregates, the rapid clearance process provokes focal inflammatory changes.

Therefore, patients exhibiting lower baseline fluid amyloid levels endure a significantly heightened lecanemab ARIA risk. Furthermore, this local clearance mechanism weakens cerebral vessel integrity, resulting in transient hyperpermeability and fluid extravasation into surrounding tissue. In addition, preexisting endothelial damage and microvascular fragility exacerbate plasma leakage across the compromised blood-brain barrier during active therapy. Because baseline fluid testing directly captures the true extent of vascular amyloid burden, clinicians gain an indispensable prognostic parameter. Thus, incorporating comprehensive biofluid profiles into routine clinical evaluations helps physicians identify vulnerable individuals and proactively counsel families prior to antibody administration.

Differentiating ARIA-E and ARIA-H in Clinical Practice

Clinicians classify amyloid-related neuroimaging findings into two distinct yet frequently overlapping radiographic presentations. Specifically, ARIA-E signifies vasogenic edema or sulcal fluid accumulation, which appears as hyperintense signal changes on T2-fluid-attenuated inversion recovery magnetic resonance sequences. In contrast, ARIA-H represents microhemorrhages and superficial cortical siderosis, which radiologists visualize using susceptibility-weighted or gradient-echo sequences. Both phenomena reflect transient disruptions in neurovascular architecture during active amyloid clearance.

Fortunately, the vast majority of observed cases remain clinically silent and resolve spontaneously after temporary treatment withholding. However, symptomatic patients occasionally experience persistent headaches, visual disturbances, confusion, gait imbalance, or acute focal neurological deficits. Therefore, attending clinicians must maintain intense diagnostic vigilance throughout the initial treatment cycles. Moreover, concurrent cerebral amyloid angiopathy significantly amplifies the frequency of cortical microhemorrhagic complications in older adults. Consequently, establishing standardized magnetic resonance imaging protocols ensures timely detection of both edematous and hemorrhagic variations, preserving patient safety before severe clinical symptoms emerge.

Evaluating Genetic Susceptibility and Imaging Screening

Although cerebrospinal fluid biomarkers yield critical predictive information, genetic status remains a fundamental determinant of therapeutic safety. Specifically, the apolipoprotein E epsilon 4 allele constitutes the most established genetic risk factor for treatment-associated neurovascular complications. Homozygous carriers demonstrate a substantially higher incidence of both vasogenic edema and cortical microbleeds compared to noncarriers. Consequently, global expert guidelines recommend comprehensive genetic counseling and testing prior to initiating monoclonal antibody therapy.

Moreover, baseline magnetic resonance scans establish indispensable structural baselines before drug initiation. Physicians must meticulously quantify preexisting cerebral microbleeds, previous cortical infarcts, and advanced white matter hyperintensities. For example, established clinical practice guidelines strictly advise against administering lecanemab to patients possessing more than four baseline microhemorrhages or evidence of severe superficial siderosis. Therefore, clinicians achieve optimal safety outcomes by synthesizing genetic status, structural neuroimaging findings, and baseline fluid biomarkers. Consequently, this comprehensive screening paradigm effectively shields vulnerable individuals from preventable neurovascular harm during therapeutic interventions.

Surveillance Protocols and Practical Management Strategies

Achieving optimal clinical outcomes with antiamyloid therapies requires disciplined adherence to standardized surveillance schedules. Because the majority of neuroimaging abnormalities develop during the first six months of treatment, protocols mandate regular magnetic resonance monitoring at strict intervals. Specifically, clinicians must obtain brain scans prior to the fifth, seventh, and fourteenth infusions. Furthermore, teams must immediately conduct unscheduled imaging whenever patients report sudden headaches, cognitive fluctuations, or visual disturbances.

When surveillance imaging identifies mild asymptomatic vasogenic edema, clinicians may often continue infusions under intensified radiographic observation. In contrast, moderate or severe abnormalities mandate immediate suspension of therapy until complete radiographic resolution occurs on follow-up imaging. In addition, healthcare providers must exercise extreme caution regarding concurrent anticoagulant therapy, because anticoagulation markedly elevates the hazard of devastating intracerebral hemorrhages. Therefore, active collaboration among neurologists, neuroradiologists, and clinical teams guarantees rapid complication detection and effective therapeutic management throughout treatment.

Frequently Asked Questions

What are the primary symptoms associated with ARIA?

Although most patients experiencing imaging abnormalities remain completely asymptomatic, symptomatic individuals present with noticeable neurological disturbances. Most frequently, patients report mild to moderate headaches, sudden visual disturbances, persistent dizziness, or new confusion. Less commonly, severe cases produce localized weakness, nausea, or unexpected seizures. Therefore, healthcare providers must educate both patients and caregivers to recognize these warning signs promptly, allowing clinical teams to arrange urgent diagnostic magnetic resonance imaging before further complications develop.

How does baseline CSF amyloid-beta 42 predict imaging abnormalities?

Significantly lowered baseline cerebrospinal fluid amyloid-beta 42 directly indicates heavy deposition of amyloid within cerebral parenchyma and cortical blood vessel walls. Consequently, when therapeutic monoclonal antibodies bind and mobilize these extensive vascular aggregates, the local vessel walls experience heightened inflammatory disruption. This sudden clearance increases microvascular permeability, thereby promoting both parenchymal fluid leakage and microvascular extravasation. Clinicians can thus utilize baseline fluid biomarker concentrations to identify highly susceptible patients who warrant heightened post-infusion radiographic vigilance.

When should clinicians resume treatment after an ARIA episode?

Treatment resumption decisions depend strictly upon the radiographic severity, clinical symptom status, and follow-up imaging findings. Typically, clinicians pause antiamyloid infusions immediately upon identifying symptomatic or moderate-to-severe neuroimaging abnormalities. Therapy may resume at the previous dosage once follow-up magnetic resonance imaging confirms full radiographic resolution and the patient achieves complete symptom recovery. However, recurrent severe edema or macrohemorrhage necessitates permanent discontinuation to prevent catastrophic neurological injury and ensure patient safety.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Takahashi R et al. Lower baseline cerebrospinal fluid amyloid-β 42 is associated with amyloid-related imaging abnormalities during real-world lecanemab treatment. J Alzheimers Dis. 2026 Sep 15. doi: 10.1177/13872877261488874. PMID: 42742530.
2. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21.
3. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate use recommendations. Alzheimers Dement. 2023;19(7):3153-3162.